Which weight loss injection is safest — and what does that actually mean?

You've searched 'safest', here's the honest starting point

Imagine you've spent twenty minutes reading forum threads, each one confident about a different answer. One post swears by Wegovy; another says tirzepatide is newer and therefore riskier; a third mentions something called a 'fat-burning jab' that a clinic in your city is offering. It's a reasonable place to feel confused.

The clearest way through it is this: in the UK, only two injectable medicines are currently licensed by the MHRA specifically for weight management in adults, tirzepatide, sold as Mounjaro, and semaglutide, sold as Wegovy. Anything outside that list is either unlicensed for this purpose, from an unverified source, or both. When people ask about the safest weight loss injections, the honest answer is that licensed, clinically assessed, and genuinely supplied through the UK chain is where safety begins, not ends.

The word 'safe' also needs unpacking. No medicine is without side effects. What the licensing process means is that the MHRA has reviewed the full trial data and judged that the benefits outweigh the risks for the indicated population. Both Mounjaro and Wegovy carry a Black Triangle (▼) symbol, meaning the MHRA continues to monitor them actively as newer medicines. That is not a red flag, it is the system working as intended.

It is also worth knowing that L-carnitine, popular in some aesthetic clinics, is not licensed as a weight management medicine in the UK. Our overview of L-carnitine injections explains what the evidence does and doesn't show.

How the two licensed injections compare on safety and tolerability

Both Mounjaro and Wegovy work by reducing appetite and slowing the rate at which food leaves your stomach. Their side-effect profiles overlap heavily because of this shared mechanism. Nausea, loose stools, constipation, indigestion and reduced appetite itself are the most commonly reported effects, typically worst in the first few weeks of a new dose level and settling as the body adjusts. The NHS tirzepatide medicines page and the equivalent semaglutide page list these in full, and are worth bookmarking before you start.

Pancreatitis (inflammation of the pancreas) is a less common but serious risk flagged for all GLP-1 medicines. The MHRA issued a Drug Safety Update on this in January 2026, advising patients to seek urgent medical help for severe stomach pain that reaches through to the back, with or without vomiting. That symptom should never be waited out.

One practical checking habit worth building into your routine: before each weekly dose, look at the pen window to confirm the liquid is clear and colourless. Cloudy, discoloured, or particle-containing solution should never be injected. It takes about ten seconds and is the kind of check that catches a storage issue before it becomes a problem.

On clinical trial evidence, SURMOUNT-5 (a head-to-head trial published in the New England Journal of Medicine in 2025) found tirzepatide produced greater average weight loss than semaglutide 2.4mg over 72 weeks. Neither result automatically makes one 'safer' than the other; tolerability is individual, and the right choice for you depends on your health history, other medicines you take, and your prescriber's assessment.

Why 'safest' and 'cheapest' are not the same search

A question our prescribers hear regularly is whether a cheaper listing elsewhere means the same medicine for less money. Sometimes it does. Often it does not.

The MHRA has seized roughly 20 million doses of illegally traded weight loss medicines (worth around £45 million) including counterfeit pens found to contain insulin rather than the labelled medicine. People were hospitalised. The risk is not theoretical. If a seller is offering these medicines without requiring a clinical assessment first, that is the clearest sign to walk away. There is no discount worth taking on a medicine that may not contain what the label says.

Thinking about the cost of private treatment is completely reasonable. Our weight loss treatments page sets out what a legitimate prescription service includes (consultation, clinical review, and aftercare) and why transparent pricing covers all of those things, not just the pen. For broader context on how the two licensed options compare, the weight loss injections overview is a practical starting point.

The MHRA also makes it straightforward to report any suspect sellers directly through the Yellow Card scheme, something worth knowing if you encounter listings that look off.

Who these medicines are licensed for, and when a prescriber decides

Both Mounjaro and Wegovy are licensed for adults. Tirzepatide is licensed for adults with a BMI of 30 or above, or 27 or above with at least one weight-related health condition such as high blood pressure, high cholesterol or type 2 diabetes. Semaglutide follows a similar framework. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance.

Neither medicine is recommended during pregnancy, while breastfeeding, or when trying to conceive. They are not licensed for anyone under 18. Certain conditions (a history of pancreatitis, medullary thyroid cancer, or MEN2) require close prescriber scrutiny and may mean one or both are not appropriate.

BMI alone does not determine suitability. That is why a prescriber reviews the whole picture: your current medicines, your medical history, your goals. If you want to understand what that assessment actually involves, how to get weight loss injections walks through the process step by step. And if you have a specific question about safety for your situation, this page on injection safety covers the most common concerns in detail.

When you're ready, a free consultation with our clinical team is the place to find out whether treatment is suitable for you.